A procurement mistake that is easy to make: treating human coagulation factor VIII (FVIII) and factor IX (FIX) as if they were two strengths of the same haemophilia treatment. They are not. They are two different proteins, and their deficiencies cause two different diseases — haemophilia A and haemophilia B — that are treated with different concentrates. A buyer who merges the two lines, or who accepts a quotation that swaps one for the other, has ordered a product that corrects a different deficiency than the tender specifies.
This comparison is written for licensed importers, distributors and tender authorities. It explains what each factor is, how the two diseases differ, and how the distinction should be reflected in a specification. It is deliberately explicit about what wanyoda supplies, so there is no ambiguity at the quoting stage.
The one-sentence difference
Factor VIII and factor IX are two different proteins in the blood-clotting cascade. A deficiency of factor VIII causes haemophilia A; a deficiency of factor IX causes haemophilia B. The two diseases are clinically distinct, are treated with different factor concentrates, and are registered as separate products with separate approval numbers.
Side-by-side comparison
| Dimension | Factor VIII | Factor IX |
|---|---|---|
| What it is | Coagulation factor VIII protein | Coagulation factor IX protein |
| Deficiency causes | Haemophilia A | Haemophilia B |
| Relative frequency | More common (majority of haemophilia) | Less common |
| Source | Fractionated from pooled human plasma | Fractionated from pooled human plasma |
| Treatment | Factor VIII concentrate | Factor IX concentrate |
| Interchangeable? | No — separate products, separate indications | |
| wanyoda portfolio | Supplied (200 IU, plasma-derived) | Not currently supplied |
The portfolio line matters at the quoting stage: wanyoda supplies human coagulation Factor VIII, but Factor IX concentrate is not part of the current export portfolio. That is a product-line fact, not a substitution — and it is stated up front so a Factor IX enquiry is not met with an incorrect Factor VIII quotation.
Why the difference matters at procurement
The distinction shows up in three places the buying side has to get right.
Separate tender lines
Factor VIII and factor IX concentrates treat different diseases, so they appear as separate lines in tenders and in the essential-medicine and reimbursement frameworks of most markets. They are not interchangeable, and they are not fungible units of "clotting factor".
Separate registration dossiers
Each concentrate holds its own registration certificate and its own batch release pathway. The dossier that registers Factor VIII does not register Factor IX, and the import licence in the destination market names the specific factor. Mixing the two at the dossier stage delays the whole file.
Same logistics, different paperwork
Both are lyophilised plasma-derived concentrates that move at 2–8 °C, protected from light, so a single validated cold chain can serve both. But the batch release certificate, the certificate of analysis and the approval reference are product-specific — one cold chain, two document sets.
How to decide which one you need
The decision belongs to the diagnosis named in the tender or the purchase request:
- If the requirement names haemophilia A or factor VIII deficiency, the line is Factor VIII.
- If the requirement names haemophilia B or factor IX deficiency, the line is Factor IX.
- If the requirement is ambiguous, stop and ask for the diagnosis before quoting — the two concentrates are not alternatives, and guessing is how a wrong order is placed.
For a Factor VIII line, wanyoda can quote the product directly with its approval reference and registration dossier. For a Factor IX line, the buyer should specify the requirement to a factor IX manufacturer, as that product is outside the current wanyoda portfolio.
Frequently asked questions
Are Factor VIII and Factor IX the same thing?
No. They are two different proteins in the coagulation cascade. A deficiency of factor VIII causes haemophilia A, and a deficiency of factor IX causes haemophilia B. They are treated with different factor concentrates and are not interchangeable.
Which factor concentrate does wanyoda supply?
wanyoda supplies human coagulation Factor VIII concentrate (200 IU, plasma-derived). Factor IX concentrate is not currently part of the export portfolio. Buyers seeking factor IX should specify it separately and confirm availability with a factor IX manufacturer.
Do Factor VIII and Factor IX concentrates need the same cold chain?
Both are lyophilised plasma-derived concentrates that are shipped and stored at 2–8 °C protected from light and must not be frozen. The same validated cold chain can generally serve both, though the two lines are registered and documented separately.
Which one is more common?
Haemophilia A (factor VIII deficiency) is more common than haemophilia B (factor IX deficiency). Factor VIII accounts for the large majority of haemophilia cases, which is one reason factor VIII concentrate is the higher-volume procurement line in most markets.
Should Factor VIII and Factor IX be separate tender lines?
Yes. They treat different diseases, carry different approval numbers and are quoted separately. Merging the two lines, or accepting a quotation that substitutes one factor for the other, places the wrong product against the specification.
Where to go next
- Human Coagulation Factor VIII — full specification and approval reference for the Factor VIII line.
- Factor VIII vs PCC — how Factor VIII differs from a four-factor prothrombin complex concentrate.
- Documents a Chinese plasma supplier must provide — the document set that proves a consignment is lawful and in-spec.
- Product index — the full plasma-derived portfolio, by manufacturer.